• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis.挖掘社交媒体数据以调查患者对类风湿关节炎改善病情抗风湿药药物治疗的看法。
Ann Rheum Dis. 2020 Nov;79(11):1432-1437. doi: 10.1136/annrheumdis-2020-217333. Epub 2020 Sep 3.
2
Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.类风湿关节炎生物制剂治疗患者在传统合成改善病情抗风湿药物间转换的经济负担及治疗模式
Clin Ther. 2016 May;38(5):1205-16. doi: 10.1016/j.clinthera.2016.03.013. Epub 2016 Apr 2.
3
Sentiment analysis of social media posts on pharmacotherapy: A scoping review.社交媒体药物治疗相关帖子的情感分析:范围综述。
Pharmacol Res Perspect. 2020 Oct;8(5):e00640. doi: 10.1002/prp2.640.
4
Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity.生物改善病情抗风湿药物(bDMARDs)、靶向合成 DMARDs(tsDMARDs)和生物类似物 DMARDs(bsDMARDs)联合甲氨蝶呤治疗泰国高疾病活动度类风湿关节炎患者的成本-效用分析。
BMC Health Serv Res. 2023 May 31;23(1):561. doi: 10.1186/s12913-023-09595-1.
5
Factors influencing clinician prescribing of disease-modifying anti-rheumatic drugs for inflammatory arthritis: A systematic review and thematic synthesis of qualitative studies.影响临床医生为炎症性关节炎开具疾病修正抗风湿药物的因素:系统评价和定性研究的主题综合分析。
Semin Arthritis Rheum. 2022 Aug;55:151988. doi: 10.1016/j.semarthrit.2022.151988. Epub 2022 Feb 27.
6
Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study.比较生物制剂与常规合成改善病情抗风湿药在合并 COPD 的类风湿关节炎中的安全性:一项真实世界人群研究。
Rheumatology (Oxford). 2020 Apr 1;59(4):820-827. doi: 10.1093/rheumatology/kez359.
7
Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.药物治疗类风湿关节炎的疗效:系统文献研究为 2019 年更新的 EULAR 类风湿关节炎管理建议提供信息。
Ann Rheum Dis. 2020 Jun;79(6):744-759. doi: 10.1136/annrheumdis-2019-216656. Epub 2020 Feb 7.
8
Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.调查德克萨斯州类风湿性关节炎医疗补助受助者开始使用生物性改善病情抗风湿药物的时间以及药物依从性和持续性。
Clin Ther. 2016 Mar;38(3):646-54. doi: 10.1016/j.clinthera.2016.01.022. Epub 2016 Feb 18.
9
Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis.疾病修正抗风湿药物治疗类风湿关节炎患者的医疗效果。
J Manag Care Spec Pharm. 2019 Aug;25(8):879-887. doi: 10.18553/jmcp.2019.25.8.879.
10
Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.真实世界中类风湿关节炎患者的特征和疾病修饰抗风湿药物的使用:一项跨国研究。
Clin Rheumatol. 2023 Apr;42(4):1047-1059. doi: 10.1007/s10067-022-06478-4. Epub 2022 Dec 19.

引用本文的文献

1
Using Natural Language Processing and Social Media Data to Understand the Lived Experience of People with Fibromyalgia.利用自然语言处理和社交媒体数据来了解纤维肌痛患者的生活体验。
Healthcare (Basel). 2024 Dec 11;12(24):2511. doi: 10.3390/healthcare12242511.
2
Artificial intelligence for predicting treatment responses in autoimmune rheumatic diseases: advancements, challenges, and future perspectives.人工智能在预测自身免疫性风湿病治疗反应中的应用:进展、挑战和未来展望。
Front Immunol. 2024 Oct 22;15:1477130. doi: 10.3389/fimmu.2024.1477130. eCollection 2024.
3
Perceptions towards biologic and biosimilar therapy of patients with rheumatic and gastroenterological conditions.对患有风湿性和胃肠疾病患者的生物制剂及生物类似药治疗的看法。
BMC Rheumatol. 2022 Dec 23;6(1):79. doi: 10.1186/s41927-022-00309-4.
4
Analysis of the Evolution of User Emotion and Opinion Leaders' Information Dissemination Behavior in the Knowledge Q&A Community during COVID-19.分析 COVID-19 期间知识问答社区中用户情绪和意见领袖信息传播行为的演变。
Int J Environ Res Public Health. 2021 Nov 22;18(22):12252. doi: 10.3390/ijerph182212252.
5
The Promises and Perils of Social Media for Pediatric Rheumatology.社交媒体在儿科风湿病学中的利弊
Rheum Dis Clin North Am. 2022 Feb;48(1):233-243. doi: 10.1016/j.rdc.2021.09.005.
6
#Covid4Rheum: an analytical twitter study in the time of the COVID-19 pandemic.Covid4Rheum:COVID-19 大流行时期的推特分析研究。
Rheumatol Int. 2020 Dec;40(12):2031-2037. doi: 10.1007/s00296-020-04710-5. Epub 2020 Sep 29.

本文引用的文献

1
Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study.老年类风湿关节炎患者中七种生物制剂的药物耐受性和停药原因 - ANSWER 队列研究。
PLoS One. 2019 May 8;14(5):e0216624. doi: 10.1371/journal.pone.0216624. eCollection 2019.
2
A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.一项托法替布作为单药或与背景下的常规合成疾病修饰抗风湿药物联合治疗 3 期类风湿关节炎人群的安全性的汇总分析。
Semin Arthritis Rheum. 2018 Dec;48(3):406-415. doi: 10.1016/j.semarthrit.2018.07.006. Epub 2018 Jul 19.
3
How patients' use of social media impacts their interactions with healthcare professionals.患者使用社交媒体如何影响他们与医疗保健专业人员的互动。
Patient Educ Couns. 2018 Mar;101(3):439-444. doi: 10.1016/j.pec.2017.08.015. Epub 2017 Aug 30.
4
Patient Beliefs Have a Greater Impact Than Barriers on Medication Adherence in a Community Health Center.在社区卫生中心,患者信念对药物依从性的影响大于障碍因素。
J Am Board Fam Med. 2017 May-Jun;30(3):331-336. doi: 10.3122/jabfm.2017.03.160129.
5
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.生物制剂或托法替布用于初治类风湿关节炎患者:一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2017 May 8;5(5):CD012657. doi: 10.1002/14651858.CD012657.
6
Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users.类风湿关节炎患者联合使用改善病情抗风湿药治疗的依从性与治疗结局:新使用者与现有使用者的纵向研究
Rheumatol Int. 2017 Jun;37(6):897-904. doi: 10.1007/s00296-017-3655-z. Epub 2017 Feb 3.
7
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.托法替布治疗类风湿关节炎长达8.5年的长期安全性:来自全球临床试验数据的综合分析
Ann Rheum Dis. 2017 Jul;76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31.
8
Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach.采用离散选择法研究类风湿关节炎治疗中的患者偏好。
Patient Prefer Adherence. 2016 Nov 1;10:2217-2228. doi: 10.2147/PPA.S117774. eCollection 2016.
9
Medication adherence in patients with rheumatoid arthritis: why do patients not take what we prescribe?类风湿关节炎患者的药物依从性:为何患者不服用我们开的药?
Rheumatol Int. 2016 Nov;36(11):1535-1542. doi: 10.1007/s00296-016-3566-4. Epub 2016 Sep 24.
10
Preference for pharmaceutical formulation and treatment process attributes.对药物制剂和治疗过程属性的偏好。
Patient Prefer Adherence. 2016 Jul 27;10:1385-99. doi: 10.2147/PPA.S101821. eCollection 2016.

挖掘社交媒体数据以调查患者对类风湿关节炎改善病情抗风湿药药物治疗的看法。

Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis.

作者信息

Sharma Chanakya, Whittle Samuel, Haghighi Pari Delir, Burstein Frada, Sa'adon Roee, Keen Helen Isobel

机构信息

Rheumatology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

Rheumatology, The Queen Elizabeth Hospital, Woodville South, South Australia, Australia.

出版信息

Ann Rheum Dis. 2020 Nov;79(11):1432-1437. doi: 10.1136/annrheumdis-2020-217333. Epub 2020 Sep 3.

DOI:10.1136/annrheumdis-2020-217333
PMID:32883653
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7569383/
Abstract

OBJECTIVES

We hypothesise that patients have a positive sentiment regarding biological/targeted synthetic disease modifying anti-rheumatic drugs (b/tsDMARDs) and a negative sentiment towards conventional synthetic agents (csDMARDs). We analysed discussions on social media platforms regarding DMARDs to understand the collective sentiment expressed towards these medications.

METHODS

Treato analytics were used to download all available posts on social media about DMARDs in the context of rheumatoid arthritis. Strict filters ensured that user generated content was downloaded. The sentiment (positive or negative) expressed in these posts was analysed for each DMARD using sentiment analysis. We also analysed the reason(s) for this sentiment for each DMARD, looking specifically at efficacy and side effects.

RESULTS

Computer algorithms analysed millions of social media posts and included 54 742 posts about DMARDs. We found that both classes had an overall positive sentiment. The ratio of positive to negative posts was higher for b/tsDMARDs (1.210) than for csDMARDs (1.048). Efficacy was the most commonly mentioned reason in posts with a positive sentiment and lack of efficacy was the most commonly mentioned reason for a negative sentiment. These were followed by the presence/absence of side effects in negative or positive posts, respectively.

CONCLUSIONS

Public opinion on social media is generally positive about DMARDs. Lack of efficacy followed by side effects were the most common themes in posts with a negative sentiment. There are clear reasons why a DMARD generates a positive or negative sentiment, as the sentiment analysis technology becomes more refined, targeted studies could be done to analyse these reasons and allow clinicians to tailor DMARDs to match patient needs.

摘要

目的

我们假设患者对生物性/靶向合成改善病情抗风湿药物(b/tsDMARDs)持积极态度,而对传统合成药物(csDMARDs)持消极态度。我们分析了社交媒体平台上有关DMARDs的讨论,以了解对这些药物表达的总体态度。

方法

使用Treato分析工具下载社交媒体上关于类风湿关节炎背景下DMARDs的所有可用帖子。严格的筛选确保下载用户生成的内容。使用情感分析对这些帖子中针对每种DMARD表达的情感(积极或消极)进行分析。我们还分析了每种DMARD产生这种情感的原因,特别关注疗效和副作用。

结果

计算机算法分析了数百万条社交媒体帖子,其中包括54742条关于DMARDs的帖子。我们发现这两类药物总体上都呈积极态度。b/tsDMARDs的积极帖子与消极帖子的比例(1.210)高于csDMARDs(1.048)。疗效是积极情感帖子中最常提及的原因,而缺乏疗效是消极情感帖子中最常提及的原因。其次分别是消极或积极帖子中副作用的有无。

结论

社交媒体上的公众舆论对DMARDs总体持积极态度。消极情感帖子中最常见的主题是缺乏疗效,其次是副作用。DMARDs产生积极或消极情感有明确原因,随着情感分析技术的不断完善,可以进行针对性研究来分析这些原因,使临床医生能够根据患者需求调整DMARDs的使用。